Over the past few years, infants have gained access to immunization products that prevent Respiratory syncytial virus (RSV) infections, including maternal vaccines and next-generation monoclonal antibody passive immunization.
During the 2024-2025 RSV season, these products have been well-received, as RSV infections can lead to serious respiratory conditions in children, such as bronchiolitis and pneumonia.
Most infants (68%) become infected with RSV in the first year of life, and nearly all (97%) by the age of 2 years.
Read More
